Janssen begins Phase III study of diabetes drug canagliflozin
Janssen Research & Development (Janssen) has started a global, multicentre CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial of Invokana (canagliflozin) in patients with type 2 diabetes and d… (Source: Drug Development Technology)
Source: Drug Development Technology - February 25, 2014 Category: Pharmaceuticals Source Type: news
Phase 3 results demonstrate safety and efficacy profile of Invokana (canagliflozin) as add-on therapy for type 2 diabetes in adults
Janssen Research & Development, LLC (Janssen) have announced results from a new 52-week analysis of Phase 3 results showing INVOKANA® (canagliflozin) provided substantial improvements in glycemic control in patients with type 2 diabetes who are inadequately controlled on metformin and a sulfonylurea, two of the most commonly used antihyperglycemic therapies. These results are among a total of 12 abstracts for canagliflozin being presented at the 49th European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Spain... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
EU Gives Green Light to Canagliflozin for DiabetesEU Gives Green Light to Canagliflozin for Diabetes
Canagliflozin is soon to become the second SGLT-2 inhibitor approved for the treatment of type 2 diabetes in the European Union, having received EMA endorsement yesterday. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Invokana Tops Januvia as Third-Line Therapy, With DrawbacksInvokana Tops Januvia as Third-Line Therapy, With Drawbacks
In patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin provided better glucose control than adding sitagliptin, but with increased genital infections. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Invokana (Canagliflozin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 15, 2013 Category: Drugs & Pharmacology Source Type: news
canagliflozin, Invokana
Title: canagliflozin, InvokanaCategory: MedicationsCreated: 4/10/2013 2:13:00 PMLast Editorial Review: 4/10/2013 2:13:18 PM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - April 10, 2013 Category: Drugs & Pharmacology Source Type: news
canagliflozin, Invokana
Title: canagliflozin, InvokanaCategory: MedicationsCreated: 4/10/2013 2:13:00 PMLast Editorial Review: 4/10/2013 2:13:18 PM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - April 10, 2013 Category: Endocrinology Source Type: news
Invokana (canagliflozin) for the Treatment of Type 2 Diabetes
Invokana (canagliflozin) is indicated to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. It was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals. (Source: Drug Development Technology)
Source: Drug Development Technology - April 4, 2013 Category: Pharmaceuticals Source Type: news
FDA Approves Invokana to Treat Type 2 Diabetes
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 1, 2013 Category: Journals (General) Source Type: news
Invokana (canaglifozin) For Type 2 Diabetes Approved By FDA
The FDA has approved Johnson & Johnson's Invokana (canaglifozin) tablets, to be used with exercise and diet, for adults with type 2 diabetes to improve glycemic control. Type 2 diabetes affects approximately 24 million Americans. Patients eventually tend to have complications from high blood sugar levels, including kidney damage, nerve damage, blindness and heart disease. Mary Parks, M.D... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 31, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
Invokana Wins F.D.A. Approval for Diabetes Treatment
Clinical trials for the drug, Invokana, showed that it improved patients’ blood-sugar levels and also led to weight loss and reductions in blood pressure. (Source: NYT Health)
Source: NYT Health - March 29, 2013 Category: Consumer Health News Authors: By KATIE THOMAS and ANDREW POLLACK Tags: Johnson & Johnson JNJ NYSE Drugs (Pharmaceuticals) Food and Drug Administration Wells Fargo Company WFC NYSE Invokana Diabetes Bristol Myers Squibb Company BMY NYSE Source Type: news
U.S. FDA Approves INVOKANA? (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes(Mar 29, 2013)
RARITAN, N.J., March 29, 2013 ? Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA? (canagliflozin) for the treatment of adults with type 2 diabetes. INVOKANA? is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States. It is also the only oral, once-daily medication available in the United States offering improved glycemic control while also showing reduced body weight and systolic blood pressure in clinical trials..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 29, 2013 Category: Pharmaceuticals Source Type: news
Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes(Mar 7, 2013)
BEERSE, March 7, 2013 ? Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat adult patients with type 2 diabetes..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 7, 2013 Category: Pharmaceuticals Source Type: news
Horizon scanning: US FDA panel recommends approval of canagliflozin for type 2 diabetes
Source: BioSpace
Area: News
According to BioSpace, the Endocrinologic and Metabolic Drugs Advisory Committee of the US FDA has voted 10-5 to recommend the approval of canagliflozin for the treatment of type 2 diabetes in adults.
Canagliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that works by blocking the reabsorption of glucose by the kidney, thus increasing glucose excretion and lowering blood glucose levels. People with type 2 diabetes reabsorb greater amounts of glucose than those without diabetes, and this may contribute to elevated glucose levels. The advisory committee ...
Source: NeLM - News - January 14, 2013 Category: Drugs & Pharmacology Source Type: news
FDA Panel Likes Janssen Diabetes Drug
(MedPage Today) -- After a day of deliberations, an FDA advisory committee concluded that the agency should approve Invokana (canagliflozin), a novel agent for type 2 diabetes. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 11, 2013 Category: Cardiology Source Type: news
